Skip to main content

Diabetic Eye Problems

0
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Santen
SantenCA - Emeryville
1 program
3% Diquafosol tetrasodiumN/A1 trial
Active Trials
NCT05193331Unknown70Est. Nov 2023

Trial Timeline

Clinical trial activity over time

2023
2024
2025
2026
Santen3% Diquafosol tetrasodium

Clinical Trials (1)

Total enrollment: 70 patients across 1 trials

NCT05193331Santen3% Diquafosol tetrasodium

Use of 3% Diquafosol Topical Ophthalmic Solution for Diabetic Dry Eye

Start: Apr 2023Est. completion: Nov 202370 patients
N/AUnknown

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.